A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.

Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.

By Meagan Parrish • Aug. 28, 2026

Pharma’s new CEOs to watch

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

By Kelly Bilodeau • Aug. 27, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Legend’s interim CEO sees a shorter path to the next era of CAR-T

Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.

By Sy Mukherjee • Aug. 25, 2026

The scientific research pharma leaders keep sharing — and why

Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.

By Kelly Bilodeau • Aug. 20, 2026

Trump nominates policy aide Overton to lead FDA

Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.

By Kristin Jensen • Updated Aug. 19, 2026

How Helus’ new CEO plans to scale its psychedelic drug pipeline

Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?

By Kelly Bilodeau • Aug. 18, 2026

BioNTech’s oncology pivot comes with a new CEO

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

By Kelly Bilodeau • Aug. 14, 2026

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

By Alexandra Pecci • Aug. 12, 2026

Specialty pharma has an infrastructure problem, and IT can’t solve it alone

Technology to enable the specialty patient journey is becoming IT's problem, but the fix isn't becoming the expert.

By Danny Sigurdson, Founder and CEO, Courier Health • Aug. 3, 2026

What pharma leaders wish they knew on day 1

PharmaVoice checked in with four life sciences executives after they landed a new role. Now they’re looking back on what they learned.

By Alexandra Pecci • July 9, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

Recent pharma exec shake-ups signal strategic shifts

Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.

By Kelly Bilodeau • June 24, 2026

Pfizer CFO departs for consumer goods sector

Dave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.

By Maura Webber Sadovi • Updated June 18, 2026

As M&A rebounds, here’s how pharmas can prepare to seal a deal

Drugmakers that aren’t ready when financial opportunity knocks could get caught flat-footed in a competitive market.

By Kelly Bilodeau • June 18, 2026

The biotech market is rebounding. So where are the executive jobs?

The industry is showing favorable economic signs, but biotech companies are still taking a measured approach to hiring leaders.

By Kelly Bilodeau • June 15, 2026

The ‘secret sauce’ for hiring for biotech CEOs

Biotech company architect Stella Vnook shares her formula for finding the right chief executives.

By Alexandra Pecci • May 27, 2026

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

By Jacob Bell • May 27, 2026

China’s biotech rise sparks new US industry alliance

The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.

By Kelly Bilodeau • May 21, 2026

Summer reads with unexpected lessons for biopharma leaders

From an inspiring rags-to-riches journey to a heroic rescue story at sea, here are a few books recommended by biopharma execs and what they can teach about leadership.

By Alexandra Pecci • May 19, 2026

HHS, industry leaders spar over drug pricing, TrumpRx and PBMs

Debate about drug costs erupted among prominent healthcare figures, including Dr. Oz, Mark Cuban, Calley Means and PhRMA in Washington, D.C., but they all agreed on one thing: The system is broken.

By Michael Gibney • April 23, 2026

Who is Dr. Houman Hemmati, potentially CBER’s next leader?

Where the rumored frontrunner stands on key issues like vaccines and public health policy.

By Kelly Bilodeau • April 20, 2026

Roche’s DAC investment; Big Pharma’s lavish CEO bumps

Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.

By PharmaVoice Staff • April 17, 2026

How J&J plans to hit $100B in revenue this year

Johnson & Johnson leaders have laid out a plan to reach record revenue this year while opening the door to more down the road.

By Michael Gibney • April 16, 2026

5 notable pharma CEO pay hikes in 2025

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”

By Alexandra Pecci • April 14, 2026